Longeveron vs MediciNova
LGVN and MNOV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LGVN and MNOV compare
Longeveron and MediciNova are about the same size, with market caps of $67.3M and $66.0M.
MediciNova keeps more of each dollar of sales as profit, with a net margin of −1168% compared with −1978% at Longeveron.
MediciNova scores higher on the StockData Score (7 against 5 for Longeveron), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LGVN | MNOV |
|---|---|---|
| Size and price | ||
| Market cap | $67.3M | $66.0M |
| Share price | $2.11 | $1.34 |
| Change, 1 year | −69.0% | −13.5% |
| Change, 5 years | −99.9% | −58.4% |
| Beta (5Y) | 1.44 | −0.00 |
| Employees | 37 | 6 |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 56.7× (better) | 71.7× |
| P/B | 6.5× | 1.8× (better) |
| FCF yield | −30.5% | −13.8% (better) |
| Growth | ||
| Revenue growth (TTM) | −42.7% | – |
| Revenue growth, 5Y average | −26.6% | – |
| Profitability | ||
| Gross margin | 69.8% | – |
| Operating margin | −1993% | −1287% (better) |
| Net margin | −1978% | −1168% (better) |
| FCF margin | −1730% | −991% (better) |
| Return on equity | −204% | −25.6% (better) |
| Return on invested capital | −1412% | −76.6% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 2.63 | 8.75 (better) |
| Altman Z-score | −9.42 | −3.11 (better) |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 1.5% | 10.5% |
| Held by insiders | 43.8% | 12.8% |
| Insider net buying, 12 months | – | −$1.7M |
| Short interest, % of float | 0.88% | 0.66% |
Go deeper
- LGVN stock overview
- LGVN income statement
- LGVN valuation and score
- MNOV stock overview
- MNOV income statement
- MNOV valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.